SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
Zhipu AI Raises HK$31.37 Billion in Discounted Share Sale to Accelerate AI Growth 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
SK Hynix’s $28B U.S. IPO Draws Strong Demand as AI Chip Boom Fuels Investor Interest 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy 
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge 
Apple Tests China's CXMT Memory Chips as DRAM Maker Gains Global Market Share 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
Wolfspeed Sues Navitas Over GaN and SiC Patent Infringement 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Japan Regional Bank Stocks Drop After Zentoshin Bankruptcy Sparks Credit Risk Concerns 
Bernstein Names IAG, Ryanair as Top European Airline Stocks Ahead of Earnings 
Oil and LNG Tankers Turn Back as Strait of Hormuz Security Risks Escalate 
MORRISTOWN, N.J., May 01, 2018 -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, announced today that the Company will report financial results for the first quarter ended March 31, 2018, after the market close on Thursday, May 10, 2018. Pernix management will also host a conference call at 4:30pm Eastern Time to discuss the results.
| Date: | Thursday, May 10 | ||||||||
| Time: | 4:30 PM ET | ||||||||
| Toll free (U.S.): | 888-394-8218 | ||||||||
| International: | 323-701-0225 | ||||||||
| Conference ID: | 7026871 | ||||||||
| Webcast: | http://public.viavid.com/index.php?id=129150 | ||||||||
About Pernix Therapeutics
Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company is currently focused on the therapeutic areas of Pain and Neurology, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its internal sales force and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc.
To learn more about Pernix Therapeutics, visit www.pernixtx.com.
CONTACT
Investor Relations
Bob Yedid
LifeSci Advisors, LLC
[email protected]
